Abstract:Background Anthracyclines including doxorubicin are essential components of many cancer chemotherapy regimens, but their cardiotoxicity severely limits their use. New strategies for treating anthracycline-induced cardiotoxicity (AIC) are still needed. Anthracycline-induced DNA double-strand break (DSB) is the major cause of its cardiotoxicity. However, DSB-based drug screening for AIC has not been performed possibly due to the limited throughput of common assays for detecting DSB. To discover new therapeutic candidates for AIC, here we established a method to rapidly visualize and accurately evaluate the intranuclear anthracycline-induced DSB, and performed a screening for DSB inhibitors. Results First, we constructed a cardiomyocyte cell line stably expressing EGFP-53BP1, in which the formation of EGFP-53BP1 foci faithfully marked the doxorubicin-induced DSB, providing a faster and visible approach to detecting DSB. To quantify the DSB, we used a deep learning-based image analysis method, which showed the better ability to distinguish different cell populations undergoing different treatments of doxorubicin or reference compounds, compared with the traditional threshold-based method. Subsequently, we applied the deep learning-assisted high-content screening method to 315 compounds and found three compounds (kaempferol, kaempferide, and isoliquiritigenin) that exert cardioprotective effects in vitro. Among them, the protective effect of isoliquiritigenin is accompanied by the up-regulation of HO-1, down-regulation of peroxynitrite and topo II, and the alleviation of doxorubicin-induced DSB and apoptosis. The results of animal experiments also showed that isoliquiritigenin maintained the myocardial tissue structure and cardiac function in vivo. Moreover, isoliquiritigenin did not affect the killing of HeLa and MDA-MB-436 cancer cells by doxorubicin and thus has the potential to be a lead compound to exert cardioprotective effects without affecting the antitumor effect of doxorubicin. Conclusions Our findings provided a new method for the drug discovery for AIC, which combines phenotypic screening with artificial intelligence. The results suggested that isoliquiritigenin as an inhibitor of DSB may be a promising drug candidate for AIC.

Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor

Deep Learning-Assisted High-Content Screening Identifies Isoliquiritigenin As an Inhibitor of DNA Double-Strand Breaks for Preventing Doxorubicin-Induced Cardiotoxicity

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Identification of Compounds Against Anti‐apoptotic Bcl‐2 Protein Using Docking Studies

Structure-Based Discovery of an Organic Compound That Binds Bcl-2 Protein and Induces Apoptosis of Tumor Cells

Development of 3‐phenyl‐n‐(2‐(3‐phenylureido)ethyl)‐thiophene‐2‐sulfonamide Compounds As Inhibitors of Antiapoptotic Bcl‐2 Family Proteins

Systems Biology Network-Based Discovery of a Small Molecule Activator BL-AD008 Targeting AMPK/ZIPK and Inducing Apoptosis in Cervical Cancer.

Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone

The Novel Benzothiazole Derivative PB11 Induces Apoptosis via the PI3K/AKT Signaling Pathway in Human Cancer Cell Lines

Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain

A Novel Bcl-X-L Inhibitor Z36 That Induces Autophagic Cell Death In Hela Cells

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Structure-based virtual screening for identification of potential CDC20 inhibitors and their therapeutic evaluation in breast cancer

Induction of Apoptosis and Down-Regulation of Bcl-XL in Cancer Cells by a Novel Small Molecule, 2[[3-(2,3-Dichlorophenoxy)propyl]amino]ethanol.

Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein

Anlotinib Inhibits the Growth of Breast Cancer Cells by Promoting Autophagy and Apoptosis Via the Akt/GSK-3α Signalling Pathway

Combining structure-based pharmacophore modeling and machine learning for the identification of novel BTK inhibitors

Bcl-2 Family Proteins As Targets for Anticancer Drug Design